UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

The New England journal of medicine, 2015-04, Vol.372 (18), p.1689-1699

2015

Volltextzugriff (PDF)

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor

Drug metabolism and disposition, 2016-08, Vol.44 (8), p.1201-1212

2016

Volltextzugriff (PDF)

In vitro models for the prediction of in vivo performance of oral dosage forms

European journal of pharmaceutical sciences, 2014-06, Vol.57, p.342-366

2014

Volltextzugriff (PDF)

Determining bioequivalence possibilities of long acting injectables through population PK modelling

European journal of pharmaceutical sciences, 2022-12, Vol.179, p.106296-106296, Article 106296

2022

Volltextzugriff (PDF)

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

Cancer chemotherapy and pharmacology, 2016-04, Vol.77 (4), p.767-776

2016

Volltextzugriff (PDF)

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

British journal of clinical pharmacology, 2018-06, Vol.84 (6), p.1156-1169

2018

Volltextzugriff (PDF)

Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin

British journal of clinical pharmacology, 2018-12, Vol.84 (12), p.2877-2888

2018

Volltextzugriff (PDF)

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non‐Small‐Cell Lung Cancer and in Healthy Volunteers

Journal of clinical pharmacology, 2018-04, Vol.58 (4), p.474-484

2018

Volltextzugriff (PDF)

STAT2 deficiency and susceptibility to viral illness in humans

Proceedings of the National Academy of Sciences - PNAS, 2013-02, Vol.110 (8), p.3053-3058

2013

Volltextzugriff (PDF)

Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report

Journal of pharmaceutical sciences, 2021-02, Vol.110 (2), p.594-609

2021

Volltextzugriff (PDF)

The effects of pharmaceutical excipients on drug disposition

Advanced drug delivery reviews, 2007-12, Vol.59 (15), p.1482-1503

2007

Volltextzugriff (PDF)

High-resolution gene expression profiling for simultaneous kinetic parameter analysis of RNA synthesis and decay

RNA (Cambridge), 2008-09, Vol.14 (9), p.1959-1972

2008

Volltextzugriff (PDF)

Oral bioavailability of cinnarizine in dogs: Relation to SNEDDS droplet size, drug solubility and in vitro precipitation

European journal of pharmaceutical sciences, 2013-01, Vol.48 (1-2), p.339-350

2013

Volltextzugriff (PDF)

Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis

PLoS biology, 2011-03, Vol.9 (3), p.e1000598-e1000598

2011

Volltextzugriff (PDF)

Exploring a model-based analysis of patient derived xenograft studies in oncology drug development

PeerJ (San Francisco, CA), 2021-01, Vol.9, p.e10681-e10681, Article e10681

2021

Volltextzugriff (PDF)

Correction to: Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products

The AAPS journal, 2020-12, Vol.23 (1), p.7-7, Article 7

2020

Volltextzugriff (PDF)

Self-Adaptive Air-path Health Management for a Heavy Duty-Diesel Engine

International journal of prognostics and health management, 2023-02, Vol.14 (3)

2023

Volltextzugriff (PDF)

Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products

The AAPS journal, 2020-07, Vol.22 (5), p.97-97, Article 97

2020

Volltextzugriff (PDF)

An Investigation into the Utility of a Multi-compartmental, Dynamic, System of the Upper Gastrointestinal Tract to Support Formulation Development and Establish Bioequivalence of Poorly Soluble Drugs

The AAPS journal, 2012-06, Vol.14 (2), p.196-205

2012

Volltextzugriff (PDF)

Viral mediated redirection of NEMO/IKKγ to autophagosomes curtails the inflammatory cascade

PLoS pathogens, 2012-02, Vol.8 (2), p.e1002517-e1002517

2012

Volltextzugriff (PDF)

Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series

Pharmaceutics, 2022-05, Vol.14 (5), p.1010

2022

Volltextzugriff (PDF)

Clinical Relevance of Dissolution Testing in Quality by Design

The AAPS journal, 2008-06, Vol.10 (2), p.380-390

2008

Volltextzugriff (PDF)

Meta-Analysis Identification of Highly Robust and Differential Immune-Metabolic Signatures of Systemic Host Response to Acute and Latent Tuberculosis in Children and Adults

Frontiers in genetics, 2018-10, Vol.9, p.457-457

2018

Volltextzugriff (PDF)

Comparative analysis of small RNAs released by the filarial nematode Litomosoides sigmodontis in vitro and in vivo

PLoS neglected tropical diseases, 2019-11, Vol.13 (11), p.e0007811-e0007811

2019

Volltextzugriff (PDF)

The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance

Journal of pharmaceutical sciences, 2014-11, Vol.103 (11), p.3377-3397

2014

Volltextzugriff (PDF)

1 – 25 von 960

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(779)
Mit Volltextzugriff
(803)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor

In vitro models for the prediction of in vivo performance of oral dosage forms

Determining bioequivalence possibilities of long acting injectables through population PK modelling

Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

Effect of multiple‐dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin

The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non‐Small‐Cell Lung Cancer and in Healthy Volunteers

STAT2 deficiency and susceptibility to viral illness in humans

Applications of Physiologically Based Biopharmaceutics Modeling (PBBM) to Support Drug Product Quality: A Workshop Summary Report

The effects of pharmaceutical excipients on drug disposition

High-resolution gene expression profiling for simultaneous kinetic parameter analysis of RNA synthesis and decay

Oral bioavailability of cinnarizine in dogs: Relation to SNEDDS droplet size, drug solubility and in vitro precipitation

Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis

Exploring a model-based analysis of patient derived xenograft studies in oncology drug development

Correction to: Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products

Self-Adaptive Air-path Health Management for a Heavy Duty-Diesel Engine

Integrated Multi-stakeholder Systems Thinking Strategy: Decision-making with Biopharmaceutics Risk Assessment Roadmap (BioRAM) to Optimize Clinical Performance of Drug Products

An Investigation into the Utility of a Multi-compartmental, Dynamic, System of the Upper Gastrointestinal Tract to Support Formulation Development and Establish Bioequivalence of Poorly Soluble Drugs

Viral mediated redirection of NEMO/IKKγ to autophagosomes curtails the inflammatory cascade

Developing Clinically Relevant Dissolution Specifications (CRDSs) for Oral Drug Products: Virtual Webinar Series

Clinical Relevance of Dissolution Testing in Quality by Design

Meta-Analysis Identification of Highly Robust and Differential Immune-Metabolic Signatures of Systemic Host Response to Acute and Latent Tuberculosis in Children and Adults

Comparative analysis of small RNAs released by the filarial nematode Litomosoides sigmodontis in vitro and in vivo

The Biopharmaceutics Risk Assessment Roadmap for Optimizing Clinical Drug Product Performance

Suchergebnisse filtern